Daniel Ferry
Managing Director of LifeSci Advisors
Replay available
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Marcio Souza
President and Chief Executive Officer
Tim Kelly
Chief Financial Officer
Megan Sniecinski
Chief Operating Officer
Steve Petrou
President of Research and Development
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Praxis Precision Medicines, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.051 -- 00:00:05.194 Good day and thank you for standing by. Welcome to the Praxis Precision Medicines Second 00:00:05.194 -- 00:00:09.316 Quarter 2026 Financial Results Conference Call. 00:00:09.316 -- 00:00:12.919 At this time, all participants are in a listen-only mode. 00:00:12.919 -- 00:00:17.361 After the speaker's presentation, there will be a question and answer session. 00:00:17.361 -- 00:00:21.524 To ask a question, you will need to press star 11 on your phone. 00:00:21.524 -- 00:00:25.626 You will then hear an automated message advising that your hand is raised. 00:00:25.626 -- 00:00:29.605 To withdraw your question, please press star 11 again. 00:00:29.605 -- 00:00:33.526 Please be advised that today's conference is being recorded. 00:00:33.526 -- 00:00:38.068 I would now like to hand the conference over to our first speaker today, Daniel Ferry, 00:00:38.068 -- 00:00:44.890 Managing Director of LifeSci Advisors. Daniel, please go ahead. 00:00:45.071 -- 00:00:51.113 Good morning, and welcome to the Praxis Precision Medicines second quarter 2026 financial 00:00:51.113 -- 00:00:54.134 results and business update conference call. 00:00:54.134 -- 00:00:58.296 This call is being webcast live and can be accessed on the investor section of Praxis' 00:00:58.296 -- 00:01:02.211 website at www.praxismedicines.com. 00:01:03.913 -- 00:01:08.135 Please note that remarks made during this call may contain forward-looking statements 00:01:08.135 -- 00:01:12.897 within the meaning of the Private Securities Litigation Reform Act of 1995. 00:01:12.897 -- 00:01:17.459 These may include statements about the company's future expectations and plans, clinical 00:01:17.459 -- 00:01:21.260 development timelines, and financial projections. 00:01:21.321 -- 00:01:25.362...